Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells

Oncogene

Volumn 27, Issue 22, 2008, Pages 3134-3144

  Hajji, N ^a   Wallenborg, K ^a   Vlachos, P ^a   Nyman, U ^a   Hermanson, O ^a   Joseph, B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

AIF; Apoptosis; Bcl xL; HDAC inhibitor; NSCLC

Indexed keywords

APOPTOSIS INDUCING FACTOR; CASPASE 3; CYTOCHROME C; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BCL XL; TRICHOSTATIN A; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; DRUG EVALUATION, PRECLINICAL; ETOPOSIDE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 43749087604     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210976     Document Type: Article

References (36)

1. Cande C, Vahsen N, Garrido C, Kroemer G. (2004). Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ 11: 591-595.
2. Choi YH. (2005). Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 27: 473-479.
3. Desagher S, Martinou JC. (2000). Mitochondria as the central control point of apoptosis. Trends Cell Biol 10: 369-377.
4. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528.
5. Gallego MA, Joseph B, Hemstrom TH, Tamiji S, Mortier L, Kroemer G et al. (2004). Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene 23: 6282-6291.
6. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. (2006). Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res 66: 11298-11304.
7. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
8. Henderson C, Brancolini C. (2003). Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. Drug Resist Updat 6: 247-256.
9. Hsu YT, Youle RJ. (1998). Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 273: 10777-10783.
10. Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P, Zhivotovsky B. (2001). Defective caspase-3 relocalization in non-small cell lung carcinoma. Oncogene 20: 2877-2888.
11. Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R, Zhivotovsky B. (2002). Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 21: 65-77.
12. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Korobowicz E, Korszen-Pilecka I et al. (2006). Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 51: 61-69.
13. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW et al. (2006). SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15: 187-191.
14. Kruidering M, Evan GI. (2000). Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life 50: 85-90.
15. La Thangue NB. (2004). Histone deacetylase inhibitors and cancer therapy. J Chemother 16: 64-67.
16. Lei X, Huang Z, Zhong M, Zhu B, Tang S, Liao D. (2007). Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. Acta Biochim Biophys Sin (Shanghai) 39: 344-350.
17. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192.
18. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202.
19. Marks PA, Jiang X. (2005). Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4: 549-551.
20. Martinou JC, Green DR. (2001). Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2: 63-67.
21. Minucci S, Pelicci PG. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
22. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. (2005). Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 102: 3697-3702.
23. Pham NA, Hedley DW. (2001). Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DNA-damaging agents. Exp Cell Res 264: 345-352.
24. Roucou X, Montessuit S, Antonsson B, Martinou JC. (2002). Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochem J 368: 915-921.
25. Rundall BK, Denlinger CE, Jones DR. (2005). Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer. Surgery 138: 360-367.
26. Schniewind B, Heintz K, Kurdow R, Ammerpohl O, Trauzold A, Emme D et al. (2006). Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. J Carcinog 5: 25.
27. Shimizu S, Konishi A, Kodama T, Tsujimoto Y. (2000). BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA 97: 3100-3105.
28. Slee EA, Keogh SA, Martin SJ. (2000). Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 7: 556-565.
29. Villar-Garea A, Esteller M. (2004). Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171-178.
30. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944-950.
31. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT. (2003). Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 22: 2236-2247.
32. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA et al. (2002). Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513.
33. Zamzami N, Kroemer G. (2001). The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2: 67-71.
34. Zangemeister-Wittke U, Leech SH, Olie RA, Simoes-Wust AP, Gautschi O, Luedke GH et al. (2000). A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 6: 2547-2555.
35. Zhivotovsky B, Joseph B, Orrenius S. (1999). Tumor radiosensitivity and apoptosis. Exp Cell Res 248: 10-17.
36. Zhivotovsky B, Wade D, Gahm A, Orrenius S, Nicotera P. (1994). Formation of 50kbp chromatin fragments in isolated liver nuclei is mediated by protease and endonuclease activation. FEBS Lett 351: 150-154.